Jul 22
|
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
|
Jul 22
|
Sanofi to Acquire UK Biotech Vicebio for $1.15 Billion to Bolster Respiratory Vaccine Pipeline
|
Jul 22
|
Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion
|
Jul 22
|
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
|
Jul 22
|
NYC Council's Firewall Starts in District 5--with a Bombshell Named Alina
|
Jul 21
|
Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal
|
Jul 21
|
SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-Bell
|
Jul 21
|
Sanofi concludes Blueprint Medicines acquisition
|
Jun 15
|
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
|
Jun 15
|
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
|
Jun 15
|
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
|
Jun 15
|
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
|
Jun 12
|
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
Jun 10
|
Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand
|
Jun 10
|
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
|
Jun 9
|
Sanofi: Information concerning the total number of voting rights and shares - May 2025
|
Jun 9
|
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
|
Jun 9
|
Regeneron and Sanofi’s dupilumab shows promise in AD trial
|
Jun 9
|
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care
|